The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Here are some of the major companies whose stocks moved on the week’s news.

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...